Figure 5
From: A panel of emerging EMT genes identified in malignant mesothelioma
The mRNA expression of top genes COL5A2, ITGAV, SPARC and ACTA2 associated with overall survival of epithelioid subtype and all MPM patients in TCGA database. (A) Tumor cell genes COL5A2 and ITGAV expression correlated with overall survival in MESO cohort. Median survival is 13.61mon in COL5A2hi and 24.89mon in COL5A2lo, respectively, hazard ratio: 2.318, 95% CI of ratio 1.424–3.774; Median survival is 15.02mon in ITGAVhi and 24.07mon in ITGAVlo, respectively, hazard ratio: 1.791, 95% CI of ratio 1.116–2.875. (B) Non-tumor cell genes SPARC and ACTA2 expression correlated with overall survival in MESO cohort. Median survival is 13.61mon in SPARChi and 26.14mon in SPARClo, respectively, hazard ratio: 2.337, 95% CI of ratio 1.441–3.791; Median survival is 14.17mon in ACTA2hi and 24.36mon in ACTA2lo, respectively, hazard ratio: 2.035, 95% CI of ratio 1.266–3.270. (C) Tumor genes COL5A2 and ITGAV expression correlated with overall survival of epithelioid subtype. Median survival is 15.22mon in COL5A2hi and 28.37mon in COL5A2lo, respectively, hazard ratio: 2.823, 95% CI of ratio 1.566–5.088; Median survival is 19.43mon in ITGAVhi and 25.94mon in ITGAVlo, respectively, hazard ratio: 1.946, 95% CI of ratio 1.107–3.422. (D) Non-tumor genes SPARC and ACTA2 expression correlated with overall survival of epithelioid subtype. Median survival is 17.95mon in SPARChi and 27.06mon in SPARClo, respectively, hazard ratio: 2.179, 95% CI of ratio 1.230–3.862; Median survival is 14.76mon in ACTA2hi and 27.16mon in ACTA2lo, respectively, hazard ratio: 2.148, 95% CI of ratio 1.213–3.803.
